Fig. 2.

FAST proteins increase the anti-tumor activity of VSV in a primary 4T1 model. (A) Schematic of the primary 4T1 tumor model and treatment schedule. (B) 4T1 tumor volume was assessed in untreated tumor-bearing mice and mice treated with VSV-GFP, VSV-p14, VSV-p15 (1 × 10⁷), or VSV-p15 (1 × 10⁸) (n = 4–14 per group). Comparison of curves was performed via linear mixed-effect modeling analysis: ^*p < 0.05 compared to untreated, ^†p < 0.05 compared to VSV-GFP, ^‡p < 0.05 compared to VSV-p14